Physician profile
Leo Fink
NPI 1386604957
$673.66
in general payments reported to CMS, 2019-2025
12 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $53.15 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221.49 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $123.09 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $73.11 | 2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $67.89 | 2025 | Farxiga, Airsupra |
| Amgen INC. | $44.34 | 2025 | Repatha, Otezla |
| Abbott Laboratories | $25.26 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.06 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.03 | 2025 | |
| Inspire Medical Systems, INC. | $21.86 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $20.38 | 2025 | Gvoke Hypopen |
| Ionis Pharmaceuticals, INC. | $17.68 | 2025 | Tryngolza |
| Shield Therapeutics INC | $14.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.